Letters sent to healthcare professionals in November 2016

A summary of recent letters sent to relevant healthcare professionals, to inform them of updated safety information.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 14 December 2016

• Therapeutic area: Cancer, Dermatology, Immunosuppression and transplantation, Infectious disease, Psychiatry, Rheumatology

In November 2016, the following letters were sent to relevant healthcare professionals:

• apremilast (Otezla▼): risk of suicidal ideation and behaviour
• lenalidomide (Revlimid▼): new advice about viral reactivation

Article citation: Drug Safety Update vol 10 issue 5, December 2016: 3.

Published 14 December 2016